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Background: Most patients with episodic tension-type headache treat headache episodes with over-the-counter
medication. Combination analgesics containing caffeine may be more effective and as well tolerated as monotherapy.
The aim of this study was to evaluate the efficacy of the combination of acetylsalicylic acid, acetaminophen (paracetamol)
and caffeine in episodic tension-type headache using recently recommended endpoints.
Methods: Four randomized, controlled trials of identical design in 1,900 patients with episodic tension-type
headache comparing acetylsalicylic acid, acetaminophen and caffeine vs. acetaminophen or placebo were pooled.
Analysis populations were ‘all headache episodes’ and those with ‘severe pain at baseline’. Post-hoc defined primary
endpoint: headache episodes pain-free at 2 h. Secondary endpoints: headache episodes pain-free at 1 h, headache
response at 2 h (mild or no pain), degree of interference with daily activities.
Results: 6,861 headache episodes were treated, including 2,215 severe headache episodes. The proportion of
headache episodes pain-free at 2 h was significantly higher with the triple combination (28.5%) vs. acetaminophen
(21.0%) and placebo (18.0%) (p < 0.0001), and similarly for those severe at baseline (20.2% vs. 12.1% and 10.8%;
p≤ 0.0003). A similar pattern of superiority was observed for secondary endpoints. The triple combination was generally
well tolerated.
Conclusions: The combination of acetylsalicylic acid, acetaminophen and caffeine is effective and well tolerated in
episodic tension-type headache, and significantly superior to acetaminophen with regard to being pain-free at 2 h,
headache response at 2 h and ability to return to daily activities, even in those with pain rated severe at baseline.
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Tension-type headache (TTH) is by far the most
prevalent primary headache [1,2]. In general, most
patients with episodic TTH never consult a physician
[3] and treat the headache episodes with over-the-
counter (OTC) medication [4]. The most frequently
used drugs are acetylsalicylic acid (ASA), acetamino-
phen (APAP; paracetamol) and non-steroidal anti-
inflammatory drugs (NSAIDs) such as ibuprofen. In
fact, such drugs are the only options available, as spe-
cific migraine medications such as triptans are not ef-
fective in TTH [5], while opioids increase the risk of
medication-overuse headache [6]; neither is recom-
mended for use in TTH [7]. However, some patients
or headache episodes might not respond to mono-
therapy, and patients may overuse an analgesic in
order to relieve their pain. Therefore, combination
therapies with ASA, APAP and caffeine were deve-
loped to provide superior efficacy using lower doses
of analgesics compared with therapeutic doses of
monotherapy [8,9].
In this paper, we describe four multicenter, random-
ized, double-blind, crossover studies comparing the ef-
fectiveness of a single dose of a combination analgesic
containing ASA, APAP and caffeine vs. APAP alone or
placebo in patients with moderate or severe episodic
TTH. These studies were pooled for a meta-analysis of
the efficacy of the triple combination. The original
studies were conducted in the 1980s, and the results
were published by Migliardi et al. [10]. The purpose of
the Migliardi paper was to evaluate the effect of caf-
feine in TTH and therefore included the results of all
studies in TTH that used an analgesic–caffeine com-
bination. However, we wanted to concentrate only on
the efficacy of the triple combination (ASA, APAP and
caffeine) and hence only included four of the studies
assessed in the Migliardi paper [10]. Furthermore, the
efficacy analysis was updated to reflect endpoints that
have recently been recommended to better differentiate
among treatments in clinical trials of TTH, i.e. pain-free
after 2 h (Y/N) and headache response after 2 h (Y/N)
[11,12]. These endpoints are particularly appropriate to
guide therapeutic choices [11]. In addition, it was decided
to see how effective the triple combination was in the sub-




Adults aged 18 to 65 years of either sex diagnosed with
episodic TTH were randomized into the four studies.
The diagnostic criteria for muscle contraction or tension
headache were those that were commonly recognized at
the time the study was conducted, i.e.:a. Ache or sensation of tightness, pressure, or
constriction, widely varied in intensity, frequency,
and duration, sometimes long-lasting [13].
b. Ache or pain associated with contraction of neck,
face, and scalp muscles in the absence of permanent
structural changes; usually as part of the individual’s
reaction to life stress.
c. Headache described as being a steady ache or as a
“tightness”, “pressure”, “drawing”, or soreness of the
head.
d. Headache, commonly bilateral (sometimes
unilateral), at center near occiput and posterior
cervical region that may radiate to the temples, jaws,
portions of the face or vertex cranii or constitute a
“bandlike” constriction about the head.
e. Tenderness of the trapezius or posterior cervical
muscles on palpation may be present. At times
localized tender, taut muscle fibers may be noted.
Pressure on these areas may cause pain to spread to
adjacent portions of the head or face.
These criteria fulfil at least two of the current diagnostic
requirements for episodic TTH (i.e. bilateral location, press-
ing/tightening (non-pulsating) quality), but no indication
was given regarding the frequency or duration of headaches
[14]. In addition, the presence of other symptoms (e.g. nau-
sea, photophobia, phonophobia) was not recorded. All pa-
tients were in good general health, as determined by
medical history and review of current medications. Eligible
patients averaged at least four but no more than ten
tension-type headache episodes per month during the last
year, which usually responded to OTC analgesics. Patients
with a history of chronic, recurrent or continuous headache
episodes, vascular headache of migraine type, post-
traumatic headache or other types of headache were ex-
cluded. Institutional Review Board approval for each center
was obtained and all subjects provided written, informed
consent. All studies were conducted according to the
ethical principles of the Declaration of Helsinki.
Interventions
The three treatments administered in the studies were a
triple combination analgesic (unbranded Extra-Strength
Excedrin®, Novartis Consumer Health; two tablets, each
containing ASA 250 mg, APAP 250 mg and caffeine
65 mg) (AAC), APAP alone (unbranded Tylenol®, McNeil
Consumer Healthcare; two 500 mg caplets) and placebo.
Blinding was achieved through double-dummy dosing.
Each TTH attack was treated with a single dose of study
medication. Any rescue medication (subjects’ usual medi-
cation), as well as any medication required to treat adverse
events (AEs) during the 4 h evaluation period was re-
corded on a self-rating record. No other medication of any
kind was taken concurrently with the study medication.
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The same protocol was used for each of the four studies.
In the common incomplete block crossover study design,
each subject was randomized to one of six possible se-
quences, in which two of the three treatments were taken
over the two periods (Figure 1). The randomization was
weighted so that overall, twice as many patients dosed
with each of the two active treatments as with placebo.
The two periods were separated by a washout of at least
7 days, during which subjects took their own usual medi-
cation for any headache episodes or other pain.
Within each period, subjects treated two TTH attacks
with single doses of the study medication designated for
that period by the randomized treatment sequence. The
two treated headache episodes were separated by at least
48 h. Subjects were instructed to treat only TTH head-
ache episodes with at least moderate pain severity. At
baseline, subjects recorded the amount of any caffeine-
containing foods and beverages consumed in the preced-
ing 4 h, administered a single 4-tablet dose of the study
medication and then abstained from caffeine-containing
foods and beverages for the following 4 h. Further details
of the design can be found in the original publication of
these studies by Migliardi et al. [10].
Efficacy parameters
After dosing, subjects evaluated pain intensity hourly for
4 h on a 4-point scale (0 = none; 1 =mild; 2 =moderate;
3 = severe). The degree of interference with daily activities
was also measured on a 4-point scale (0 = no more difficult
than usual, 1 = require some additional effort, 2 =more
difficult than usual, 3 = impossible).
Data adjustment
Concomitant medications that could interfere with the
scoring of the efficacy variables were taken into consider-
ation before analysis: all pain and discomfort scores re-
corded more than 15 minutes after the subject remedicatedFigure 1 Design of the four randomized, controlled studies includedwere replaced by either the score measured at baseline or
by the last score measured before remedication, whichever
was less favorable.
Safety analysis
Adverse events were coded according to an AE coding
dictionary that was current at the time the studies were
conducted. Each AE was attributed to the study treat-
ment taken mostly recently before the AE occurred.
Meta-analysis
Data presentation and analysis
The primary endpoint of the present meta-analysis was
the percentage of treated headache episodes in which
subjects were pain-free 2 h after dosing. This outcome is
recommended by the International Headache Society
(IHS) to be primary in trials that utilize the TTH clinical
model [12]. Secondary endpoints were the percentage of
treated headache episodes pain-free 1 h after dosing and
headache response 2 h after dosing (defined as a reduc-
tion in headache intensity from moderate or severe pain
to mild or no pain). We also compared the treatments at
each hour on the degree of interference with daily activ-
ities, specifically the percent of patients who responded
‘no more difficult than usual’. Results are presented for
‘all headache episodes’, as well as for the subset with ‘se-
vere pain at baseline’. The safety data was taken directly
from Migliardi et al. [10].
Statistical methods
The statistical methods by which the individual studies
were analyzed are described in Migliardi et al. [10]. The
efficacy evaluable (EE) population for each study was de-
fined as all subjects who treated at least one headache in
both treatment periods.
For each binary outcome (pain-free [Y/N], having head-
ache response [Y/N] and whether the degree of interference
with daily activities was “no more difficult than usual”in the meta-analysis.
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each hour for each treatment over all headache episodes
experienced by all subjects pooled over the four studies
who dosed with that treatment.
To address the within-subject correlation imposed by
the crossover design, efficacy with respect to binary out-
comes was tested in a conditional logistic regression
model, stratified by subject, having main effects of period
and treatment, with baseline pain severity as a covariate
and with the interaction of period and the baseline covari-
ate. The two-way interactions of treatment with both
period and the baseline covariate were tested, but were
not found to be statistically significant and were dropped
from the model. Pairwise tests for differences in efficacy
between treatments were based on the least squares esti-
mates of the pairwise odds ratios. All tests were two-sided
and p < 0.05 was the cutoff for statistical significance. All
efficacy analyses were done in SAS for Windows Version
9.3 (SAS Institute Inc., Cary, NC).
Results
Characteristics of included studies
In total, 1,900 patients were randomized by 36 investiga-
tors (Figure 2). Of these, 1,785 patients used study medi-
cation at least once and 1,719 took at least one dose of
study medication in both treatment periods. However,
two subjects were excluded because of serious irregular-
ities: one received the same treatment in both periods
and the other provided dates of dosing in the second
treatment period that were earlier than those in the first
treatment period. Thus, 1,717 patients were included in
the EE analysis. The EE population is therefore trivially
different from the maximal population for efficacy ana-
lysis. The EE analysis comprised: 1,369 AAC patients
who treated 2,737 headache episodes; 1,376 APAP pa-
tients who treated 2,748 headache episodes; 689 placebo
patients who treated 1,376 headache episodes. In 32% of
treated episodes, severe pain was reported at baseline
(Table 1). The demographics of all patients included are
described in Table 1. Apart from headache intensity, the
patients with severe pain at baseline had similar baseline
characteristics to those with moderate pain.
Pain-free after 2 h (primary endpoint)
The proportion of all treated headache episodes that
were pain-free 2 h following treatment with AAC
(28.5%) was significantly higher compared with APAP
(21.0%) and placebo (18.0%) (p < 0.0001 vs. either) (see
Additional file 1, Figure 3). APAP was also significantly
superior to placebo (p = 0.007).
In the subgroup of treated headache episodes rated
severe at baseline, a similar outcome was observed
(Figure 3). The proportion of headache episodes that were
pain-free 2 h following treatment with AAC (20.2%) wassignificantly superior to APAP (12.1%; p < 0.0001) and pla-
cebo (10.8%; p = 0.0003). However, APAP did not differ
significantly from placebo (p = 0.71).
Pain-free after 1 h
The proportion of all treated headache episodes that
were pain-free 1 h following treatment with AAC
(8.6%) was significantly higher compared with APAP
(6.1%; p = 0.0004) and placebo (5.4%; p = 0.019) (see
Additional file 1). There was no significant difference
between APAP and placebo (p = 0.98).
In the subgroup of treated headache episodes with
pain rated severe at baseline, a similar outcome was ob-
served. The proportion of headache episodes that were
pain-free 1 h following treatment with AAC (6.5%) was
significantly superior to APAP (3.9%; p = 0.0008) and
placebo (3.1%; p = 0.015). However, APAP did not differ
significantly from placebo (p = 0.95).
Headache response after 2 h
The proportion of all treated headache episodes that had
responded 2 h following treatment with AAC (66.6%) was
significantly higher compared with APAP (58.2%) and pla-
cebo (48.8%) (p < 0.0001 vs. either) (see Additional file 2,
Figure 4). APAP was also significantly superior to placebo
(p < 0.0001).
In the subgroup of treated headache episodes with
pain rated severe at baseline, a similar outcome was ob-
served. The proportion of headache episodes that had
responded 2 h following treatment with AAC (47.4%)
was significantly superior to APAP (38.7%; p = 0.0002)
and placebo (27.0%; p < 0.0001) (Figure 4). APAP was
also significantly superior to placebo (p = 0.003).
Degree of interference with daily activities
Over the set of all treated headache episodes in the EE
population, daily activities were rated ‘no more difficult
than normal’ as early as 1 h after dosing in 30.2% of
headaches treated with AAC, increasing to 76.1% by 4 h
(Table 2). These results were significantly superior to the
corresponding results with APAP (25.8% at 1 h, increas-
ing to 69.6% at 4 h; p ≤ 0.0005) and placebo (22.8% at
1 h, increasing to 60.9% at 4 h; p ≤ 0.0001) (Table 2).
APAP was significantly superior to placebo from 2–4 h
(p ≤ 0.02).
In the subgroup of treated headache episodes with
pain rated severe at baseline, the proportion in which
daily activities were rated as ‘no more difficult than nor-
mal’ was significantly higher after treatment with AAC
vs. APAP at 1, 3 and 4 h (difference of 3.7 percentage
points at 1 h and 6 percentage points at 4 h, p ≤ 0.033)
and vs. placebo at 3 and 4 h (difference of 14.1 percent-
age points at 3 h and 16.8 percentage points at 4 h, p ≤
0.0001) (Table 2). APAP was also significantly superior
Figure 2 Summary flowchart of the patients included in the meta-analysis. Safety analysis data taken from Migliardi et al. [10]; EE = efficacy
evaluable; ITT = intention-to-treat.
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at 3 h and 10.8 percentage points at 4 h, p ≤ 0.046).
Safety profile
According to the analysis by Migliardi et al. [10], there
was a greater incidence of any AE (17%) compared with
APAP alone (10%) or placebo (9%) (Table 3). Most AEs
could be grouped into the categories of ‘stomach
discomfort’, ‘nervousness’ and ‘dizziness’; other AEs were
approximately equally distributed across the three treat-
ment groups. None of the AEs were serious, and all were
transitory.
Discussion
This post-hoc meta-analysis employed new efficacy end-
points to update the results of four randomized studies
that were performed in 1986. These endpoints (i.e. pain-
free and headache response after 2 h) have been recom-
mended to better differentiate among treatments inclinical trials of TTH [11,12]. Results demonstrate that
AAC is effective in the treatment of episodic TTH, and
significantly superior to APAP with respect to being
pain-free at 2 h, having headache response at 2 h and
being able to return to daily activities. The beneficial ef-
fects on pain are in agreement with other studies; the re-
duction in headache pain was greater with the triple
combination vs. monotherapy, using lower doses of anal-
gesic [9,15]. However, the double combination of APAP
plus caffeine was not effective than monotherapy with na-
proxen [16].
Migliardi et al. [10] found that the triple combination
is well tolerated, with AEs that were consistent with the
known profile of the drug [10]. It was speculated that
the greater incidence of ‘nervousness’ and ‘dizziness’
could be attributed to the caffeine content; on the other
hand, the greater incidence of ‘stomach discomfort’ with
AAC was probably caused by the presence of ASA. In
contrast, the study by Diener at al. [9] included a
Table 1 Pooled characteristics of all patients included in the efficacy evaluable population (i.e. all subjects who treated at
least one headache in both treatment periods) in the four randomized, controlled studies included in the meta-analysis
Characteristic AAC APAP Placebo Total
Number of patients 1369 1376 689 1717
Number of headache episodes treated 2737 2748 1376 6861
Mean age (SD), y 34.1 (9.7) 34.1 (9.7) 34.5 (10.0) 34.2 (9.8)
Sex (F), n (%) 1129 (82.5) 1140 (82.9) 563 (81.7) 1416 (82.5)
Race, n (%)
Caucasian 1238 (90.4) 1245 (90.5) 625 (90.7) 1554 (90.5)
Other 131 (9.6) 131 (9.5) 64 (9.3) 163 (9.5)
Mean no. headache episodes/month (SD) 6.4 (2.1) 6.4 (2.1) 6.4 (2.1) 6.4 (2.1)
Mean age at onset (SD), y 22.1 (8.7)a 22.2 (8.6)b 21.9 (8.6)c 22.1 (8.6)d
Onset, n (%)
Gradual 983 (71.9) 989 (71.9) 478 (69.4) 1225 (71.4)
Rapid 385 (28.1) 386 (28.1) 211 (30.6) 491 (28.6)
Location, n (%)
Suboccipital 288 (21.0) 285 (20.7) 133 (19.3) 353 (20.6)
Occipital 411 (30.0) 388 (28.2) 201 (29.2) 500 (29.1)
Parietal 95 (6.9) 98 (7.1) 49 (7.1) 121 (7.1)
Temporal 640 (46.8) 659 (47.9) 309 (44.9) 804 (46.8)
Frontal 750 (54.8) 759 (55.2) 385 (55.9) 947 (55.2)
Whole head 205 (15.0) 205 (14.9) 106 (15.4) 258 (15.0)
Character, n (%)
Non-throbbing 404 (29.5) 397 (28.9) 207 (30.0) 504 (29.4)
Throbbing 341 (24.9) 343 (24.9) 182 (26.4) 433 (25.2)
Combination 624 (45.6) 636 (46.2) 300 (43.5) 780 (45.4)
Usual severity (history), n (%)
Mild 12 (0.9) 8 (0.6) 8 (1.2) 14 (0.8)
Moderate 789 (57.6) 784 (57.0) 375 (54.4) 974 (56.7)
Severe 546 (39.9) 563 (40.9) 293 (42.5) 701 (40.8)
Very severe 22 (1.6) 21 (1.5) 13 (1.9) 28 (1.6)
Severity at baseline, n (%)
Mild 0 (0.0) 1 (0.04) 0 (0.0) 1 (0.01)
Moderate 1879 (68.7) 1846 (67.2) 920 (66.9) 4645 (67.7)
Severe 858 (31.3) 901 (32.8) 456 (33.1) 2215 (32.3)
Mean age at onset based on data from a1358 patients, b1364 patients, c684 patients, d1703 patients.
AAC = acetylsalicylic acid, acetaminophen, caffeine; APAP = acetaminophen; SD = standard deviation.
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results of this subgroup were not reported, the triple
combination was well tolerated in episodic TTH, and
did not result in more AEs than monotherapy (HC
Diener, unpublished data, [9]). A favorable risk-benefit
ratio was also observed in a previous study that used this
triple combination in TTH, albeit with a lower dose of
caffeine (50 mg) [15].
Clearly, the combination offers an important alterna-
tive when APAP alone is not effective enough. Caffeine,
in particular, contributes to the greater efficacy of thecombination vs. APAP alone; patients with TTH or other
pain conditions who take an analgesic without caffeine
need about 40% more medication to get the same relief
as patients taking the same analgesic with caffeine [17].
Analgesic combinations containing caffeine have been
recommended as first-line [18] or Level I [19] therapies
to manage episodic TTH.
In our pooled population, over 30% of treated head-
aches had pain rated severe at baseline – much higher
than reported by Rasmussen et al. [20]. Nevertheless,
several other studies in episodic TTH have reported
Figure 3 Proportion of all headache episodes and severe headache episodes at baseline that were pain-free at 2 h after treatment.
AAC was significantly superior to APAP and placebo for all headache episodes (p < 0.0001 vs. both) and those that were severe at baseline
(p < 0.0001 vs. APAP and p = 0.0003 vs. placebo). APAP was significantly superior to placebo for all headache episodes (p = 0.007) but not those
that were severe at baseline (p = 0.71).
Figure 4 Proportion of all headache episodes and severe headache episodes at baseline with mild or no pain at 2 h after treatment.
AAC was significantly superior to APAP and placebo for all headache episodes (p < 0.0001 for both) and for those that were severe at baseline
(p = 0.0002 vs. APAP and p < 0.0001 vs. placebo). APAP was significantly superior to placebo (p < 0.0001) for all headache episodes and those that
were severe at baseline (p = 0.003).
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Table 2 Proportion of patients who found daily activities to be ‘no more difficult than normal’ after treatment
Treatment Proportion (%) of patients who found daily activities to be ‘no more difficult than normal’
after treatment
1 h p-value 2 h p-value 3 h p-value 4 h p-value
All headache episodes
AAC (n = 2734 – 2736 over 1 h – 4 h) 30.2 AAC vs. P 0.0001 47.8 AAC vs. P <0.0001 64.8 AAC vs. P <0.0001 76.1 AAC vs. P <0.0001
APAP (n = 2738 – 2747 over 1 h – 4 h) 25.8 A vs. P 0.16 41.3 A vs. P 0.016 57.7 A vs. P <0.0001 69.6 A vs. P <0.0001
Placebo (n = 1367 – 1375 over 1 h – 4 h) 22.8 AAC vs. A 0.0005 36.3 AAC vs. A <0.0001 51.0 AAC vs. A <0.0001 60.9 AAC vs. A <0.0001
Severe at baseline
AAC (n = 856 – 858 over 1 h – 4 h) 17.1 AAC vs. P 0.18 31.1 AAC vs. P 0.079 48.1 AAC vs. P 0.0001 62.5 AAC vs. P <0.0001
APAP (n = 897 – 901 over 1 h – 4 h) 13.4 A vs. P 0.93 27.2 A vs. P 0.60 43.1 A vs. P 0.046 56.5 A vs. P 0.032
Placebo (n = 453 – 456 over 1 h – 4 h) 10.5 AAC vs. A 0.033 20.4 AAC vs. A 0.082 34.0 AAC vs. A 0.011 45.7 AAC vs. A 0.002
AAC = acetylsalicylic acid, acetaminophen, caffeine; A or APAP = acetaminophen; P = placebo.
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with severe pain [16,21,22]. However, we cannot abso-
lutely exclude the possibility that some of the treated
headaches were migraine attacks, as it is not clear
whether associated symptoms were recorded. The
phenotype of treated headache attacks might have devi-
ated from the diagnosis made by prior history. This
problem, inherent to studies of this type, has been noted
previously [23]. Nevertheless, subjects were only in-
cluded in the studies if they met criteria that adhered to
the definition of TTH at the time, matching at least two
of the criteria of episodic TTH used today [14]. In
addition, patients were excluded if they had a history of
“vascular headache of migraine type” – although it
should be noted that prior to inclusion in the studies,
headache attacks were described as throbbing (or a com-
bination of throbbing/non-throbbing) in some patients.
This type of ‘pulsating’ pain is more commonly associ-
ated with migraine, however the IHS classification does
not preclude it as a characteristic of episodic TTH [14].
Therefore, it is not unreasonable to assume that the ma-
jority of ‘severe’ headaches were in fact tension-type.
There is also a common perception that the pain asso-
ciated with episodic TTH can only be mild to moderate.
However, while it is true that the IHS states that the painTable 3 Incidence of adverse events in the safety
population (i.e. all subjects who dosed at least once
with any study medication) in the four randomized,
controlled studies (reproduced with permission from
Migliardi et al.) [10]







Any adverse event 241 (17) 136 (10) 61 (9)
Stomach upset 130 (9) 67 (5) 34 (5)
Nervousness 61 (4) 13 (1) 4 (1)
Dizziness 58 (4) 22 (2) 7 (1)
AAC = acetylsalicylic acid, acetaminophen, caffeine; APAP = acetaminophen.intensity associated with episodic TTH is typically mild
to moderate (particularly in contrast to the pain of a mi-
graine, for example, which is classed as moderate to se-
vere), the criteria do not specify that the pain has to be
mild to moderate [14]. Only two of the four characteris-
tics need to be met to diagnose episodic TTH (i.e. bilat-
eral location, pressing/tightening (non-pulsating) quality,
mild or moderate intensity, not aggravated by routine
physical activity such as walking or climbing stairs [14]),
so the pain might indeed be severe. Especially consider-
ing that the way in which patients rate the severity of
their pain can vary considerably, depending on percep-
tion – each patient has different pain thresholds and
moderate pain in one patient may be regarded as severe
by another. In the studies in our meta-analysis, the pa-
tients rated their own pain and may simply have per-
ceived it to be severe, whereas a physician might have
rated it as moderate. Despite these uncertainties, our
meta-analysis demonstrates that the triple combination
was superior to monotherapy in the subset of headache
episodes with severe pain at baseline; the proportion of se-
vere headache episodes treated that were pain-free after
2 h was 67% higher with AAC compared with APAP.
Our meta-analysis also evaluated the impact of the
triple combination on daily activities, an aspect that is
rarely studied in the literature. Even mild episodic TTH
can have an impact on cognition and attention, which
can impair performance and successful completion of
general tasks [24] and lead to reduced productivity
[3,25,26]. Therefore, any analgesic that is effective in this
regard will be of interest to patients. Our results demon-
strate that daily activities were ‘no more difficult than
normal’ from as little as 1 h after treatment with the
triple combination (Table 2).
The strength of the present study is the sample size
and the large number of treated headache episodes. The
crossover design increases the power of the trial [27]. A
limitation of the study is the long time period that has
passed since these studies were performed. Consequently,
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for the treatment of TTH were not available. Although the
design limitations cannot be addressed at this late date, we
consider them to have modest impact. In addition, it can-
not be ignored that some of the headache attacks during
the studies may have been migraine rather than episodic
TTH, as noted above. Either way, the combination of
ASA, APAP and caffeine is superior to APAP monother-
apy and placebo even in patients with severe headache
and is well tolerated.
Conclusions
Pooled data from 6,861 treated headache episodes con-
firms the efficacy of the fixed combination of acetylsali-
cylic acid, acetaminophen and placebo in the treatment
of episodic TTH. AAC was significantly superior to
1000 mg APAP and to placebo with respect to the per-
cent pain-free at 2 h, as well as the percent with head-
ache response (mild or no pain) at this point. Similar
superiority was observed in the subset of treated head-
aches with pain rated severe at baseline. In addition, sig-
nificantly more AAC patients were able to return to
their daily activities 1 h after dosing vs. either 1000 mg
APAP or placebo. AAC was generally well tolerated,
with a predictable safety profile.
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